Clinical Trial Update: A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. [Phase 3]

View source ↗

Summary

Phase 3 multi-center study evaluating PET imaging with Flurpiridaz F18 in patients with coronary artery disease completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Flurpiridaz F-18 (flurpiridaz F-18)

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-04-05